CalciMedica, Inc. (CALC)

In March 2026, CalciMedica reported its 2025 financial results and provided clinical updates, noting no drug-related toxicity with Auxora in the Phase 2 KOURAGE trial and expecting to design a pivotal program in acute pancreatitis in the first half of 2026. In January 2026, CalciMedica discontinued its Phase 2 KOURAGE trial in AKI due to safety concerns, leading to a significant stock price drop. In November 2025, CalciMedica reported its third-quarter 2025 financial results and provided clinical and corporate updates, with enrollment continuing in the Phase 2 KOURAGE trial for AKI with respiratory failure and preclinical data supporting CRAC channel inhibitors for pulmonary arterial hypertension being published. As of March 18, 2026, CalciMedica's stock price was $0.82, with a market capitalization of $12.9 million.

The provided information does not indicate any specific demand seasonality for CalciMedica, Inc.'s products or services. Demand for its potential future products would likely be driven by disease prevalence and medical need rather than seasonal patterns.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for serious illnesses driven by inflammatory and immunologic processes. Their technology inhibits calcium release-activated calcium (CRAC) channels, representing a new class of drugs. The company's major product candidates include Auxora (zegocractin), CM5480, and oral CRAC channel inhibitors. Auxora is being developed for acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury. CM5480 is being advanced for pulmonary arterial hypertension. Oral CRAC channel inhibitors are being explored for chronic inflammatory and immunologic diseases. CalciMedica operates within the Healthcare sector, specifically in Biotechnology and Drug Discovery.

CalciMedica, Inc. is headquartered in La Jolla, California, United States. The provided information does not detail a specific global or broader national geographic footprint for its operations or product distribution at this clinical stage.

The discontinuation of the Phase 2 KOURAGE trial in AKI due to safety concerns in January 2026 could potentially have a negative impact on CalciMedica's reputation. However, the positive safety review of Auxora data from the KOURAGE trial in March 2026 and the ongoing progress in the acute pancreatitis program could help mitigate some reputational concerns.

The provided search results do not contain specific information about the major institutional and individual owners of CalciMedica, Inc.